To validate the results obtained from RWD, we leveraged the liquid biopsy (LB)-based CGP data collected at baseline for a recent clinical trial, acelERA BC (NCT04576455) that enrolled 2L/3L patients with ER+/HER2- locally advanced BC or mBC41. The gene discussed is ERBB2; the disease is breast cancer.